Location: Home
  • search
  • go
  • Relate News
  • 7/5/2023SMEI Forecasts Growth of Ex-Hospital and Innovative Drug Sales Before ...
  • 7/3/2023Innovative Drug Market Share on the Rise Continuously in Recent Years:...
  • 6/26/2023PODCAST: European Businesses Glum on China, and AstraZeneca Weighs Spi...
  • 6/20/2023AstraZeneca's China Head Dismisses Reports of Potential Spinoff as 'Ru...
  • 6/18/2023AstraZeneca Considers Spinning Off of Its China Business: FT
  • 6/15/2023German Businesses Faced Reality Check in China
  • 6/15/2023Swiss Companies Find Renewed Confidence in China's Post-COVID Era
  • 6/15/2023Top Ten Listed Chinese Pharma Companies by R&D Spending in 2021/2022
  • 6/5/2023AstraZeneca Defies Geopolitics to Bet on China (FT)
  • 6/5/2023British Businesses in China: Conditionally Optimistic for 2023 (China ...
  • 6/1/2023The U.S.-Chinese Economic Relationship Is Changing—But Not Vanishing ...
  • 6/1/2023NH's DB6: China's Consumer Healthcare Market Underperformed in 2022
  • 6/1/2023NH's DB6: Top Ten Chinese CHC Brands in 2021
  • 6/1/2023NH's DB6: Chinese Consumer Healthcare Market Forecast 2027/2032
  • 6/1/2023Edelman Report Finds Chinese Trusting Pharma the Most
  • 5/31/2023Sanofi Ups Bet on China with Plan to Enhance Manufacturing and Researc...
  • 5/29/2023A Share-Listed Chinese MedPharm Cos Report Performance in 2022 with Ov...
  • 5/29/2023Review of Leading Listed Chinese Pharma Cos by R&D Spending in 2022
  • 5/22/2023SMEI: Chinese Terminal Drug Market Growth Slowed to 1.1% in 2022 (Upda...
  • 5/19/2023An AstraZeneca Executive Said the Quiet Part about China Out Loud (Qua...
  • 5/18/2023Chinese A Shared-listed Pharma Companies Report Mixed Q1/2023 Performa...
  • 5/16/2023China's Top 10 Homegrown Novel Drugs in 2022, Vaccines and Cancer Drug...
  • 5/5/2023Reshoring and Nearshoring – Is China Still Relevant? (TMD)
  • 5/4/2023AstraZeneca Places Bet on COPD as COVID Vaccine Sales Fade
  • 5/3/2023Getting Novel Drugs to China Through Special Zones (thepharmaletter)
  • 4/28/2023AstraZeneca Eyes More China Deals After Signing Three Licensing Deals
  • 4/26/2023Why Rising Demand for Healthcare Is Creating Investment Opportunities ...
  • 4/21/2023AstraZeneca Oncology R&D Head On China Biotech Innovation - Looking Ag...
  • 4/21/2023NMPA Issues the 2022 Drug Regulatory Statistics Annual Report
  • 4/12/2023Yicai: Most Chinese Regions Eye Healthcare Industry Upgrades
  • Page:4/36 Total number of articles:1059: [First][<<] [2] [3] [4] [5] [6] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group